SCHEMBL9604566

SCHEMBL9604566

CC1[C@@H](OCCOCCOCCNC(=O)CCOCC(COCCC(=O)NCCOCCOCCO[C@H]2OC(COC(=O)c3ccccc3)[C@@H](C)[C@H](C)C2C)(COCCC(=O)NCCOCCOCCO[C@H]2OC(COC(=O)c3ccccc3)[C@@H](C)[C@H](C)C2C)CC(=O)OCc2ccccc2)OC(COC(=O)c2ccccc2)[C@@H](C)[C@@H]1C

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ LMNA P02545 1/20 0.35
▸ NT5E P21589 1/20 0.33
▸ KMT2A Q03164 3/20 0.32
▸ SLC6A2 P23975 1/20 0.32
▸ SLC6A3 Q01959 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ RAB9A P51151 2/20 0.32
▸ MAPT P10636 1/20 0.32
▸ FGF1 P05230 5/20 0.32
▸ VEGFA P15692 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.31
▸ LGALS8 O00214 1/20 0.31
▸ FGF2 P09038 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17612200 0.88 SMN1; SMN2 (0.39) SMN1; SMN2LMNANT5EKMT2ASLC6A2
SCHEMBL10177589 0.88 USP2 (0.37) SMN1; SMN2LMNANT5EKMT2AFGF1
SCHEMBL15829781 0.86 SMN1; SMN2 (0.34) SMN1; SMN2KMT2ASLC6A3TDP1FGF1
SCHEMBL9604567 0.86 SMN1; SMN2 (0.34) SMN1; SMN2KMT2ASLC6A3TDP1FGF1
SCHEMBL2621427 0.86 SMN1; SMN2 (0.34) SMN1; SMN2KMT2ASLC6A3TDP1FGF1
SCHEMBL9604438 0.81 LMNA (0.40) SMN1; SMN2LMNAKMT2AMAPTFGF1
SCHEMBL2621431 0.78 SMN1; SMN2 (0.38) SMN1; SMN2LMNANT5EKMT2ASLC6A2
SCHEMBL15829782 0.76 TDP1 (0.42) LMNANT5EKMT2ASLC6A2SLC6A3
SCHEMBL9604623 0.76 TDP1 (0.42) LMNANT5EKMT2ASLC6A2SLC6A3
SCHEMBL10226142 0.76 TDP1 (0.42) LMNANT5EKMT2ASLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11666653-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2023-06-06 — — US disclosed
US-9867882-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2018-01-16 — — US disclosed
US-9370581-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-06-21 — — US disclosed
US-9370582-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-06-21 — — US disclosed
US-9352048-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-05-31 — — US disclosed
US-9290760-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2016-03-22 — — US disclosed
US-20150119445-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-04-30 — — US disclosed
US-20150119444-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-04-30 — — US disclosed
US-20150011615-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-01-08 — — US disclosed
US-8828956-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2014-09-09 — — US disclosed
US-20130178512-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC (US) 2013-07-11 — — US disclosed
US-8450467-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2013-05-28 — — US disclosed
US-20120136042-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC (US) 2012-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178512-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES LPXN, ZYX, OSTC SMN1; SMN2 3506/4885LMNA 266/4885NT5E 2246/4885
US-20150119445-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC SMN1; SMN2 3469/4885LMNA 271/4885NT5E 2334/4885
US-11666653-B2 Carbohydrate conjugates as delivery agents for oligonucleotides HAVCR2, B3GAT3, CSGALNACT1 SMN1; SMN2 2980/4885LMNA 1934/4885NT5E 1725/4885
US-20150011615-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC SMN1; SMN2 3489/4885LMNA 274/4885NT5E 2230/4885
US-20150119444-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC SMN1; SMN2 3489/4885LMNA 274/4885NT5E 2230/4885
US-20120136042-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES LPXN, ZYX, OSTC SMN1; SMN2 3506/4885LMNA 266/4885NT5E 2246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback